Cigarette smoking is the leading cause of preventable morbidity and mortality. 2 Knowledge is evolving on genetics underlying initiation, regular smoking, nicotine dependence 3 (ND), and cessation. We performed a genome-wide association study using the Fagerström Test 4 for ND (FTND) in 58,000 smokers of European or African ancestry. Five genome-wide 5 significant loci, including two novel loci MAGI2/GNAI1 (rs2714700) and TENM2 (rs1862416) 6 were identified, and loci reported for other smoking traits were extended to ND. Using the 7 heaviness of smoking index (HSI) in the UK Biobank (N=33,791), rs2714700 was consistently 8 associated, but rs1862416 was not associated, likely reflecting ND features not captured by the 9 HSI. Both variants were cis-eQTLs (rs2714700 for MAGI2-AS3 in hippocampus, rs1862416 for 10 TENM2 in lung), and expression of genes spanning ND-associated variants was enriched in 11 cerebellum. SNP-based heritability of ND was 8.6%, and ND was genetically correlated with 13 12 other smoking traits (rg=0.40-0.95) and co-morbid diseases. Our results emphasize the FTND as 13 a composite phenotype that expands genetic knowledge of smoking, including loci specific to 14 ND. 15 106 displayed the best genetic correlation with ND (Figure 3) . After applying Bonferroni correction 107 for the 53 SNPs that were available in our meta-analysis (P<9.4×10 -4 ), 17 SNPs had a 108 statistically significant and directionally consistent association with ND (Table 2). These SNPs 109 span six loci reported at genome-wide or nominal significance in prior GWAS of ND (CHRNA5-110 A3-B4 [chr15], CHRNA4 [chr20], DBH [chr9], CHRNB3 [chr8], CYP2A6 [chr19], and NOL4L 111 [near DNMT3B, chr20]) 6 and three loci not reported in prior ND GWAS-DRD2 (chr11), 112
Introduction 16
Cigarette smoking remains the leading cause of preventable death worldwide, 1 despite the 17 well-known adverse health effects. Smoking causes more than 7 million deaths annually from a 18 multitude of diseases including cancer, chronic obstructive pulmonary disease (COPD), and 19 heart disease. 1,2 Cigarette smoking is a multi-stage process consisting of initiation, regular 20 smoking, nicotine dependence (ND), and cessation. Each step has a strong genetic component 21 (for example, twin-based heritability estimates up to 70% for the transition from regular smoking 22 to ND 3,4 ), and partial overlaps are expected among the sets of sequence variants correlating with 23 the different stages, 3 evidenced by findings of the GWAS and Sequencing Consortium of 24 Alcohol and Nicotine use (GSCAN) with sample sizes up to 1.2 million individuals. 5 GSCAN 25 identified 298 genome-wide significant loci associated with initiation (ever vs. never smoking), 26 age at initiation, cigarettes per day (CPD), and/or cessation (current vs. former smoking); 259 of 27 the loci harbored significant associations with initiation. 5 
28
In comparison to other stages of smoking, known loci for ND are limited. Only six 29 reproducible, genome-wide significant loci have been identified: CHRNB3-CHRNA6 (chr8p11), 30 DBH (chr9q34), CHRNA5-CHRNA3-CHRNB4 (chr15q25), DNMT3B and NOL4L (chr20q11), 31 and CHRNA4 (chr20q13). 6 A more complete understanding of the genetics underlying ND is 32 needed, as it could help to predict the likelihood of quitting smoking, withdrawal severity, 33 response to treatment, and health-related consequences. 7-10 The Fagerström Test for ND (FTND), 34 also called the Fagerström Test for Cigarette Dependence, 11 provides a composite phenotype that 35 captures multiple behavioral and psychological features of ND. 12 Expanding upon our prior 36 analyses of studies comprising our Nicotine Dependence GenOmics (iNDiGO) Consortium, 13, 14 37 we report findings from the largest GWAS meta-analysis for ND (N=58,000; 46,213 European
38
[EUR] and 11,787 African American [AA] ancestry participants from 23 studies) to identify 39 novel genetic loci associated with ND, assess genetic correlations between ND and other 40 phenotypes and gene expression patterns, and test GSCAN-identified loci 5 for effects on ND. 43 Our cross-ancestry ND GWAS meta-analysis (λ=1.034, Supplementary Figure 1A ) 44 identified five genome-wide significant loci (Figure 1) . Associations of the lead SNPs from each 45 of these five loci are shown in Table 1 . All genome-wide significant SNP/indel associations 46 from the cross-ancestry meta-analysis are provided in Supplementary Table 5 . 47 Three of the genome-wide significant loci have known associations with ND from our 48 prior GWAS and others 6 : chr15q25 13-15 (smallest P=1.6×10 -39 for rs16969968, a well-established 49 functional missense [D398N] CHRNA5 SNP 16 ), chr20q13 13 (smallest P=1.2×10 -12 for 50 rs151176846, an intronic CHRNA4 SNP), and chr9q34 14 (smallest P=1.1×10 -8 for rs13284520, 51 an intronic DBH SNP). The loci spanning nicotinic acetylcholine receptor genes (CHRNA5-A3-52 B4 and CHRNA4), but no novel loci, were identified at genome-wide significance in the EUR-53 specific GWAS meta-analysis (λ=1.036, Supplementary Figures 1B and 2A) . No genome-wide 54 significant loci were found in the AA-specific GWAS meta-analysis (λ=1.032, Supplementary
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Cross-ancestry GWAS meta-analysis finds two novel SNP associations with ND
55
Figures 1C and 2B).
56
Two genome-wide significant loci from the cross-ancestry meta-analysis represent novel 57 associations with ND. On chr7q21, the most significant SNP (P=2.3×10 -9 ) was rs2714700, a SNP 58 between the MAGI2 and GNAI1 genes (Supplementary Figures 3A-B Figure 4A-B Neither SNP showed evidence for heterogeneity, based on the I 2 index 17 , across studies (P=0.83 67 for rs2714700 and 0.75 for rs1862416). Leave-one-study-out analyses ( Supplementary Table 6 ) 68 revealed some variability in p-values (P=3.1×10 -7 -7.4×10 -9 for rs2714700 and P=5.6×10 -9 -69 3.9×10 -6 for rs1862416), likely due to fluctuating statistical power given the significant 70 correlation between N and p-value across iterations: r=-0.65, P=8.6×10 -5 . However, there was 71 little variation in the effect sizes (range of β values corresponding to the OR for severe vs. mild 72 ND = 0.95-0.96 for rs2714700-T and 1.07-1.08 for rs1862416-T). 73 We compared the novel ND-associated SNPs with results reported for other smoking 74 traits by GSCAN. 5 Both the MAGI2/GNAI1 SNP rs2714700 and the TENM2 SNP rs1862416 75 were nominally associated at P<0.05 with ever vs. never smoking and rs2714700 with CPD in 76 consistent directions with ND; neither SNP was associated with age at initiation or smoking 77 cessation ( Supplementary Table 7 ). Because rs1862416 was located within the boundaries of a 78 genome-wide significant locus for ever smoking (chr5:164,596,435-168,114,971), we used 79 GCTA to assess the independence of association signals via conditional modeling. All 6 lead 80 SNPs in this GSCAN-identified locus were in low LD with rs1862416 (maximum r 2 =0.0047
81
[ Supplementary Figure 5 ], maximum D'=0.46), and three were nominally associated with ND 82 at P<0.05 ( Supplementary Table 8 ). Among our iNDiGO studies, rs1862416 remained 83 associated with ND in models conditioned on each GSCAN lead SNP individually (P=7.9×10 -8 -84 1.8×10 -8 ) and with all 6 SNPs taken together (P=2.2×10 -7 ). Rs2714700 was located >1 MB away 85 from any GSCAN-identified locus, so conditional modeling was not necessary. These results 86 suggest that the novel rs2714700 and rs1862416 associations with ND are independent of any 87 GSCAN-identified loci.
88
For independent testing, we analyzed the two novel SNPs (rs2714700 and rs1862416) for 89 association with HSI in the UK Biobank. Results are shown in Supplementary Table 9 . The 90 MAGI2/GNAI1 SNP, rs2714700, was associated with HSI at P=0.014, which surpassed 91 Bonferroni correction for two SNP tests, and meta-analysis of all discovery studies with UK 92 Biobank (total N=91,791) supported rs2714700-T being associated with milder ND (P=7.7×10 -93 9 ). The TENM2 SNP, rs1862416, was not associated with HSI in the UK Biobank (P=0.39).
94
To determine the factors of ND that drove the novel genome-wide associations, we 95 returned to the iNDiGO studies, tested SNP associations with each specific FTND item, and 96 combined results via cross-ancestry meta-analyses. For rs2714700, we observed the lowest p-97 values for the two items that comprise the HSI (Figure 2A) : TTFC (P=5.3×10 -4 ) and CPD 98 (P=1.1×10 -3 ). Rs2714700 was also associated at P<0.05 with difficult in refraining from smoking 99 in forbidden places (P=0.025) and the cigarette most hated to give up (P=0.030). Rs1862416 was 100 associated with TTFC (P=0.018) and two items that are not captured by the HSI: the cigarette 101 most hated to give up (P=0.015) and smoking when ill (P=0.023) ( Figure 2B) . 103 We assessed whether genome-wide significant SNPs identified for smoking traits in 104 GSCAN extended to ND using results from the cross-ancestry GWAS meta-analysis. We 105 focused on the 55 genome-wide significant SNPs from 40 loci associated with CPD, given that it
102
GWAS findings for other smoking traits extend to ND
We estimated the heritability explained by common SNPs of ND at ℎ 2 (standard error) = 115 0.086 (0.012), using LDSC 18 and the EUR-specific GWAS meta-analysis results. We also found 116 statistically significant genetic correlations of ND with 13 phenotypes (Bonferroni-corrected 117 P<0.0011; Figure 3 and Supplementary Table 3 Rs2714700, an intergenic SNP, is not a significant cis-eQTL with any gene-level 133 expression in GTEx (v8), but it was implicated as a cis-eQTL for the MAGI2-AS3 transcript in 134 hippocampus from BrainSeq 19 (N=551; P=8.5×10 -4 ). The protective allele for ND (rs2714700-T) 135 was associated with higher expression of the MAGI2-AS3 transcript ENST00000414797.5.
Gene expression data implicates target genes for novel ND-associated SNPs and identifies ND
136
Rs1862416 is annotated to enhancer histone marks in brain (specifically, germinal matrix 137 during fetal development and the developed prefrontal cortex, anterior caudate, and cingulate 138 gyrus tissues) and several other tissues in HaploReg. 20 It is also located in the promoter of CTB-139 77H17.1, which is a novel antisense RNA transcript encoded within a TENM2 intron. In GTEx, 140 rs1862416 was reported as a significant lung-specific cis-eQTL SNP TENM2. The ND risk-141 conferring allele (rs1862416-T) was associated with decreased gene-level TENM2 expression in 142 lung. CTB-77H17.1 was too lowly expressed across GTEx tissues to test its expression levels by 143 rs1862416.
144
To assess the enrichment of the EUR-specific ND GWAS meta-analysis results to 145 specific gene expression patterns, we applied LDSC-SEG 21 with reference to 205 tissues/cell 146 types with publicly available gene expression data. We observed statistically significant SNPs between MAGI2 and GNAI1 (chr7q21) and in TENM2 (chr5q34) were independent of 156 previously reported GWAS signals for any smoking trait. Three of our genome-wide significant 157 loci were known: (1) CHRNA5-CHRNA3-CHRNB4 (chr15q25) is irrefutably associated with 158 ND, as driven largely by CPD. 6 (2) Our initial GWAS meta-analysis of 5 studies (now part of the 159 iNDiGO consortium) 13 identified CHRNA4 (chr20q13) at genome-wide significance. Subsequent 160 associations were found with heavy vs. never smoking in the UK Biobank 22 and with initiation, 161 CPD, and cessation in GSCAN. 5 (3) DBH (chr9q34) was first identified as genome-wide 162 significant for smoking cessation but later associated with ND in our meta-analysis of 15 studies 163 (now part of the iNDiGO consortium) 14 and with CPD and cessation in GSCAN. 5
164
The novel ND-associated locus with lead SNP rs2714700 is intergenic between MAGI2 165 (membrane associated guanylate kinase, WW and PDZ domain containing 2) and GNAI1 (G 166 protein subunit alpha i1). We identified rs2714700 at genome-wide significance for its 167 association with ND, which was driven by CPD (unlike rs1862416), TTFC, and other FTND 168 items, indicating that this SNP association may reflect both primary and secondary features of 169 ND. Rs2714700 was also associated with HSI in the independent UK Biobank. The cis-eQTL 170 evidence for rs2714700 in the hippocampus suggests that it may influence expression of the long 171 noncoding RNA MAGI2-AS3 (MAGI2 antisense RNA 3). MAGI2-AS3 has been mainly studied 172 for its role in the progression of cancer, including glioma in the brain. 23 No genome-wide 173 significant associations have been reported within 1MB of rs2714700 in the GWAS catalog. Our 174 evidence of genome-wide significance for rs2714700 points to a novel locus that has not been 175 associated with smoking or any related trait, and its functional relevance merits further 176 investigation. 177 We also observed a genome-wide significant association of ND with rs1862416, a lung-178 specific cis-eQTL for TENM2. TENM2 encodes teneurin transmembrane protein 2, a cell surface 179 receptor that plays a fundamental role in neuronal connectivity and synaptogenesis. 24 With 180 rs1862416 residing in the promoter of CTB-77H17.1, it could influence this antisense RNA, 181 which in turn could dysregulate its sense transcript, TENM2. As an illustrative example, the 182 autism-associated SNP rs4307059 is annotated to and acts as a promoter region cis-eQTL for the 183 antisense RNA MSNP1AS (moesin pseudogene 1, antisense) that influences regulation of its 184 sense transcript, MSN. 25 However, while rs1862416 is generally indicated for its potential 185 regulatory role (i.e., enhancer and promoter annotations and cis-eQTL evidence), its specific 186 effect on either CTB-77H17.1 or TENM2 regulation in brain tissue was not evident in currently 187 available data. 188 Further, independent association testing using HSI in the UK Biobank did not yield 189 statistical significance for rs1862416. This lack of association may be due to rs1862416 Figure 5) , and we found that rs1862416 was associated with ND 209 independently from other TENM2 SNPs implicated in GSCAN. These results suggest that 210 TENM2 has pleiotropic effects on ND, traits that are genetically correlated with ND, and other 211 traits.
212
The genetics of smoking behaviors, more broadly, has rapidly evolved with the GSCAN 213 consortium having amassed a very large sample size and identified 298 genome-wide significant 214 loci for smoking traits representing single components: ever vs. never smoking, age of smoking 215 initiation, CPD, and current vs. former smoking. 5 We observed significant genetic correlations of 216 each of these smoking traits with ND, yet despite the nearly complete sharing between ND and 217 CPD specifically, our two novel ND-associated loci were not identified at genome-wide 218 significance by GSCAN (smallest P=0.033 for rs1862416-T; smallest P=0.016 for rs2714700-T), 219 suggesting that these loci are specific to ND. These observations resemble previously reported 220 patterns of genetic correlation between alcohol dependence and alcohol consumption that 221 suggested shared yet distinct genetics underlying specific measures and composite phenotypes. 40
222
Similarly, the majority of GSCAN-identified loci were trait-specific (191 of the 298 loci), where 223 the other 107 loci were pleiotropic with associations identified for two or more of the smoking 224 traits. 5 In our evaluation of GSCAN-identified loci, we corroborated associations of several 225 previously implicated loci for ND (e.g., nicotine acetylcholine receptors genes CHRNA5-A3-B4 226 and CHRNA4) and three additional loci (DRD2, C16orf97, and CHRNB2) that have not been 227 reported in prior ND GWAS. Of these loci, DRD2 is notable as a long-studied addiction 228 candidate gene 4 and its recent identification as genome-wide significant for alcohol use disorder 229 for rs4936277 41 , which is correlated (r 2 =0.94 in 1000G EUR, 0.82 in 1000G AFR) with 230 rs7125588, the top SNP identified for CPD in GSCAN and associated with ND in iNDiGO; these 231 results support a shared genetic effect of DRD2 underlying addiction. Notably, rs7125588 is not 232 correlated (r 2 =0.04 in 1000G EUR, 0.01 in 1000G AFR) with the DRD2 variant rs1800497 233 (Taq1A), which is not significantly associated with ND in iNDiGO (P=0.24).
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Other GSCAN loci were detected for the single component smoking traits but show no 235 evidence for association in our study ( Supplementary Table 10 ), suggesting that these loci 236 influence stages of smoking other than ND, or they exert weak effects on ND that we were 237 underpowered to detect. We expect that additional GSCAN-identified loci are associated with 238 ND, but their detection will require a larger sample size. These results demonstrate the utility of 239 studying the genetics of the composite ND phenotype and comparing with GWAS of other 240 smoking traits to tease apart loci that are specific to one stage (i.e., initiation, regular smoking, 241 ND, cessation) vs. loci that influence multiple stages to better understand the full spectrum of 242 smoking behaviors.
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Beyond the smoking traits, we observed significant genetic correlations between ND and 244 alcohol dependence, years of schooling, neuroticism, comorbid psychiatric traits (major The present ND GWAS meta-analysis follows two prior waves of data assembly by the 263 iNDiGO consortium (Ns=17,074 13 , 38,602 14 , and now 58,000) and is the largest to date for the 264 field. Despite still having substantially smaller sample sizes than the GSCAN GWAS, at each 265 wave, increasing sample size for diverse ancestry groups (EURs and AAs) has illuminated ND-266 associated loci, some of which are shared with other stages of smoking while others are specific 267 to ND. Our present findings underscore the complexity even within the ND phenotype, as our 268 novel loci displayed patterns of association with specific FTND items that reflect primary or 269 secondary ND features, e.g., the TENM2 SNP influenced secondary features that are not captured 270 simply by heaviness of smoking. Understanding genetic differences that underlie primary vs. 271 secondary ND may better inform treatment strategies, e.g., changing environmental cues for 272 individuals whose smoking is driven solely by primary ND features vs. treating withdrawal for 273 individuals whose ND is augmented with secondary features. 28 Studying the genetics of ND alongside other smoking traits (e.g., initiation and cessation) is key to gaining a better 275 understanding of the neurobiological perturbations that influence the trajectory of smoking 276 behaviors and their treatment implications.
277
Methods
278
We assembled 58,000 participants from 23 iNDiGO consortium studies with genome- Institutional review boards at the respective sites approved the study protocols, and all 287 participants provided written informed consent. 289 The FTND is a well-validated, widely used 6-item questionnaire that assesses 290 psychologic dependence on nicotine, with scores ranging from 0 (no dependence) to 10 (highest 291 dependence level). 12,51 As done before, 13,14 we categorized FTND scores as mild (scores 0-3), 292 moderate (scores 4-6), or severe (scores 7-10). FTND data reflected current smoking behaviors 293 at the time of interview (i.e., current FTND) or the period of heaviest smoking among ever 294 smokers (i.e., lifetime FTND). We previously found only small differences in genetic association 295 results due to any measurement variance when using current vs. lifetime FTND. 52 Two studies 296 also included low-intensity smokers, who reported <10 CPD but had no data available on other 297 FTND items; these smokers were defined as mildly dependent, given minimal phenotype 298 misclassification when comparing these FTND and CPD thresholds. 14 The other FTND items 299 were always required to define moderately and severely dependent smokers. See 
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ND GWAS meta-analysis
306
GWAS results were combined using fixed-effect inverse variance-weighted meta-307 analyses in METAL. 53 Prior to performing meta-analyses, we applied genomic control to results 308 from one study, deCODE, to adjust for inflation due to relatedness among participants (λ=1.12); 309 all other studies had low inflation (λ=0.99-1.04) ( Supplementary Table 1 ). We removed Biotechnology Information (NCBI) build 37. As before 14 , the threshold of genome-wide 314 significance was set at P = 5×10 -8 . Regional association plots of novel genome-wide significant 315 loci were constructed using LocusZoom 54 with references of either 1000G European or African 316 panels to estimate linkage disequilibrium of the lead SNP (based on smallest meta-analysis P-317 value) and surrounding SNPs. The lead SNP for each novel locus was tested for association with 318 each of the specific FTND items (Supplementary Methods) . 319 For any ND-associated SNPs located within the bounds of loci identified by GSCAN (1 320 MB surrounding the lead SNP), 5 conditional models were analyzed using our GWAS summary 321 statistics and the Genome-wide Complex Trait Analysis (GCTA) tool, adjusted for the lead SNPs 322 in GSCAN. 55, 56 To contextualize the magnitude of the observed effect sizes, we calculated odds 323 ratios (ORs) using the β estimate from the single SNP linear regression model (OR=exp[2×βSNP] 324 for severe vs. mild ND, with OR>1 corresponding to an increased risk of severe ND) and 325 compared these values across studies and ancestries using the Forest Plot Viewer. 57 327 Novel, genome-wide significant SNPs from our ND GWAS meta-analysis were tested in 328 the UK Biobank. Although all 6 items of the FTND were not collected in the UK Biobank, two 329 items (CPD and time-to-first-cigarette [TTFC]) were collected among current smokers. These 330 two items together form the heaviness of smoking index (HSI), which is highly correlated with 331 the full-scale FTND (e.g., r=0.7 among nondaily smokers and 0.9 among daily smokers). 58 We 332 derived HSI scores, ranging from 0 (no dependence) to 6 (highest dependence level), and 333 categorized them as follows: mild (scores 0-2), moderate (scores 3-4), and severe (scores 5-6).
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Independent testing using heaviness of smoking index in the UK Biobank
334
These HSI categories were highly concordant (89.3%) with our routinely used FTND categories 335 using the COGEND study, which was ascertained specifically for ND ( Supplementary   336 Methods and Supplementary Table 2 ). The final analysis dataset included 33,791 current 337 smokers (18,063 mildly, 13,395 moderately, and 2,333 severely dependent, as defined by HSI). 341 Summary statistics from the EUR-specific meta-analyses were used as input into linkage 342 disequilibrium (LD) score regression (LDSC) 18 with reference to the 1000G EUR panel to 343 estimate the SNP heritability (ℎ 2 ) of ND and its genetic correlations with 45 other complex 344 phenotypes, including other smoking, drug, and alcohol use and dependence traits, smoking-345 related health consequences (e.g., cancer, COPD, and coronary heart disease), psychiatric and 346 neurologic disorders, cognitive and educational traits, and brain volume metrics. The full list of 347 phenotypes and GWAS datasets, as obtained from LD Hub 59 or shared by the original study 348 investigators, are provided in Supplementary Table 3 . 349 Similarly, EUR-specific GWAS meta-analysis summary statistics were input into 350 stratified LDSC, as applied to specifically expressed genes (LDSC-SEG), 21 with reference to 205 351 tissues and cell types from two sources-RNA-sequencing data on 53 tissues/cell types in the in Supplementary Table 4 ). Similarly to the initial application of LDSC-SEG, 21 these two 365 To assess evidence for SNP-gene associations, novel SNPs were queried against GTEx 366 (version 8) cis-expression quantitative trait loci (cis-eQTL) results derived from SNP genotype 367 and RNA-sequencing data across 44 tissues (N=126-209 for the 13 brain tissues). 60 The GTEx 368 portal (https://gtexportal.org/home/) presents significant single-tissue cis-eQTLs, based on a 369 false discovery rate (FDR) <5%. 370 We also assessed single-tissue cis-eQTL evidence from the BrainSeq consortium that 371 includes larger sample sizes with SNP genotype and RNA-sequencing data available in two brain 372 tissues, dorsolateral prefrontal cortex (N=453) and hippocampus (N=447). 19 Of the 551 373 individuals with data available in at least one brain tissue, 286 were schizophrenia cases; 374 case/control status was included as a covariate for adjustment in the cis-eQTL analysis, as We are grateful to the many study participants, who made this work possible. The meta- Abbreviations: NCBI, National Center for Biotechnology Information; SE, standard error. Correlations were calculated using linkage disequilibrium (LD) score regression with the iNDiGO European ancestry-specific GWAS meta-analysis results for ND (N=46,213), compared with results made available via LD Hub or study investigators (see Supplementary Table 3 for original references). Phenotypes were grouped by disease/trait or measurement category, as indicated by different colorings. Point estimates equate to genetic correlation (rg) values; error bars show the 95% confidence intervals; and the dotted vertical grey line corresponds to rg=0 (no correlation with ND). Phenotypes with significant correlations (P<0.0011, α=0.05/45 tested) are bolded.
Genetic correlations of ND with other complex phenotypes and with gene expression
cis-eQTL assessment of novel ND-associated SNPs
